Israel Lowy MD, PhD

Dr. Israel Lowy is the vice president of Clinical Sciences and the head of Translational Science and of Oncology at Regeneron Pharmaceuticals, where he has focused on developing novel immunotherapies, antibody-drug conjugates, and treatments that target tumor blood vessels. Dr. Lowy is a member of CRI’s Cancer Immunotherapy Consortium (CIC) Steering Committee.